Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Effect of Binder Type and Binder Level on the Properties of Agglomerates Containing Lactose and Dibasic Calcium Phosphate Dihydrate
The authors studied the effect of the combination of binders on the flow and compressibility characteristics of the agglomerates of binary combination of lactose and dibasic calcium phosphate dihydrate.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 54-64


Figure 5, (All figures are courtesy of the authors.)
Figure 5 shows the overlay plot. Superimposing the contour of individual responses to achieve a region that satisfies the constraints for all the attributes generated the overlay plot. All combinations falling in the yellow region satisfy the selected constraints. Batch F3 falls is this region and therefore was selected as the best of the batches prepared according to the 23 factorial design. Tablets containing 30% acetaminophen and 70% agglomerates of batch F3 had friability values <1% and disintegration time <15 min. The in vitro dissolution study indicated that more than 90% of the drug released in 30 min, indicating the noninterference of the filler–binder with drug release.


Table VI: Validation of the evolved mathematical models.
Validation of the evolved mathematical models. To validate the evolved mathematical models, two check points were selected. Two batches CH1 and CH2 were prepared and evaluated (see Table VI). To further validate the model an optimum batch OPT was located using grid analysis where angle of repose was 23°, Carr's index was 12, crushing strength of blank tablet was 110 N, and crushing strength of acetaminophen containing tablets was 51 N. Close agreement was found between observed and predicted values, thus strengthening the predictability of the mathematical model.

Conclusion

Various binders were screened for their effect on agglomerates of lactose and dibasic calcium phosphate diydrate. Each binder shows marked effect on various aspects of the agglomerate. If HPMC, starch, and silicon dioxide enhance the flow properties, acacia has a negative effect on these properties. PEG increases the crushing strength of blank tablets. Guar gum increased the hardness of tablets containing acetaminophen. Combination of binders for agglomeration of lactose and DCP to yield a directly compressible product with desirable attributes could be isolated using the 23 factorial design.

Anita Lalwani* is an assistant professor in the Department of Pharmaceutics at the K.B. Institute of Pharmaceutical Education and Research, Sector-23, Gh-6 Road, Gandhinagar-382023, Gujarat, India, tel. 91 98983 20018,
Jolly Parikh is an assistant professor in the Department of Pharmaceutics at A.R. College of Pharmacy and G.H. Patel Institute of Pharmacy, Vallabh Vidyanagar-388 120, Gujarat, India.

*To whom all correspondence should be addressed.

What would you do differently? Email your thoughts about this paper to
and we may post them to the site.

References

1. G.K. Bolhuis and N.A. Armstrong, "Excipients for Direct Compaction: An Update," Pharm. Dev. Technol. 11 (1), 111?124 (2006).

2. M.C. Gohel and P.D. Jogani,"A Review of Coprocessed Directly Compressible Excipients," J. Pharm. Pharma. Sci. 8 (1), 76–93 (2005).

3. R. Linden et al., "Response Surface Analysis Applied to the Preparation of Tablets Containing a High Concentration of Vegetable Spray-Dried Extract," Drug Dev. Ind. Pharm. 26 (4), 441–446 (2000).

4. Y.K. Agrawal and K. Prakasam, "Effect of Binders on Sulfamethoxazole Tablets," J. Pharm. Sci. 77 (10), 885–888 (1988).

5. H.M. Elsabbagh, A.M. Sakr, and S.E. Abd-Elhadi, "Effect of Guar Gum on the Dissolution Rate of Ephedrine Hydrochloride and Sulphadimidine Tablets," Pharmazie 33 (11), 730–731 (1978).

6. N. Yaksel, A. Karataay, and T. Baykara, "Comparative Evaluation of Granules Made with Different Binders by a Fluidized Bed Method," Drug Dev. Ind. Pharm. 29 (4), 387-395 (2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here